ArticleJournal of biomedical research2020
Fucoidan antagonizes diet-induced obesity and inflammation in mice.
Article in Journal of biomedical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Fucoidan Treatment Improves Diabetic Hyperglycemia and Dyslipidemia in Rodents: A Systematic Review and Meta-Analysis.Nutrients · 2026Pooled it
- Anti-Obesity Effects of Sulphated Polysaccharides Derived from Marine Macro Algae or Seaweeds: A Systematic Review and Meta-Analysis.Marine drugs · 2024Pooled it
- Investigating fucoidan blend supplementation and resistance training in humans: a parallel randomized controlled trial design.Scientific reports · 2025Trial
- Adipose Tissue Aging and Natural Interventions: Potential Roles of Polyphenols and Polysaccharides.Nutrients · 2026Review
- Article
- Secret heroes of the sea: brown macroalgae and their bioactive powers-a narrative review.Frontiers in nutrition · 2026Review
- Mechanisms behind the anti-diabetic and anti-obesity effects of seaweeds or macroalgae and their bioactive compounds.World journal of diabetes · 2025Review
- Neuroprotective and Anti-Inflammatory Activity ofMarine drugs · 2025Article
- Commensal bacteria signal through TLR5 and AhR to improve barrier integrity and prevent allergic responses to food.Cell reports · 2023Article
- Preclinical insights into fucoidan as a nutraceutical compound against perfluorooctanoic acid-associated obesityFrontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is an escalating global pandemic posing a serious threat to human health. The intervention therapy using weight-reducing drugs, accompanied by lifestyle modification, is a strategy for the treatment of obesity. In the present study, we explored the role of fucoidan, a seaweed compound, on high-fat diet (HFD)-induced obesity in mice. We found that fucoidan treatment significantly reduced the body fat and caused redistribution of visceral and subcutaneous fat in HFD-fed mice. Meanwhile, fucoidan treatment inhibited adipocyte hypertrophy and inflammation in adipose tissue. Collectively, these results suggest that fucoidan may be a promising treatment for obesity and obesity-induced complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.